全文获取类型
收费全文 | 1017篇 |
免费 | 44篇 |
国内免费 | 35篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 69篇 |
妇产科学 | 5篇 |
基础医学 | 84篇 |
口腔科学 | 28篇 |
临床医学 | 121篇 |
内科学 | 177篇 |
皮肤病学 | 23篇 |
神经病学 | 19篇 |
特种医学 | 186篇 |
外科学 | 64篇 |
综合类 | 24篇 |
预防医学 | 208篇 |
眼科学 | 14篇 |
药学 | 38篇 |
中国医学 | 1篇 |
肿瘤学 | 29篇 |
出版年
2021年 | 8篇 |
2019年 | 8篇 |
2018年 | 16篇 |
2017年 | 12篇 |
2016年 | 12篇 |
2015年 | 19篇 |
2014年 | 11篇 |
2013年 | 29篇 |
2012年 | 19篇 |
2011年 | 13篇 |
2010年 | 41篇 |
2009年 | 37篇 |
2008年 | 27篇 |
2007年 | 37篇 |
2006年 | 27篇 |
2005年 | 45篇 |
2004年 | 25篇 |
2003年 | 20篇 |
2002年 | 22篇 |
2001年 | 20篇 |
2000年 | 21篇 |
1999年 | 22篇 |
1998年 | 59篇 |
1997年 | 58篇 |
1996年 | 64篇 |
1995年 | 48篇 |
1994年 | 42篇 |
1993年 | 38篇 |
1992年 | 11篇 |
1991年 | 17篇 |
1990年 | 10篇 |
1989年 | 23篇 |
1988年 | 45篇 |
1987年 | 20篇 |
1986年 | 16篇 |
1985年 | 28篇 |
1984年 | 6篇 |
1982年 | 8篇 |
1981年 | 9篇 |
1980年 | 8篇 |
1979年 | 8篇 |
1978年 | 6篇 |
1977年 | 8篇 |
1976年 | 12篇 |
1975年 | 7篇 |
1974年 | 4篇 |
1973年 | 5篇 |
1968年 | 4篇 |
1965年 | 4篇 |
1931年 | 3篇 |
排序方式: 共有1096条查询结果,搜索用时 46 毫秒
121.
122.
Vita W Jongen Thijs Reyniers Zorah MH Ypma Maarten F Schim van der Loeff Udi Davidovich Hanne ML Zimmermann Liza Coyer Mark AM van den Elshout Henry JC de Vries Kristien Wouters Tom Smekens Bea Vuylsteke Maria Prins Marie Laga Elske Hoornenborg 《Journal of the International AIDS Society》2021,24(8)
IntroductionDaily and event‐driven PrEP are both efficacious in reducing the risk for HIV infection. However, the practice of event‐driven PrEP (edPrEP) is less well studied, in particular when provided as an alternative to daily PrEP. We studied regimen preferences and switches, and sexually transmitted infection (STI) incidence.MethodsWe analysed pooled data from two prospective cohort studies among MSM: Be‐PrEP‐ared, Belgium and AMPrEP, the Netherlands. In both projects, participants could choose between daily and edPrEP at three‐monthly study visits, when they were also screened for sexually transmitted infections including hepatitis C (HCV). We assessed the proportion choosing each regimen, and the determinants of choosing edPrEP at baseline. Additionally, we compared the incidence rates (IRs) of HCV, syphilis and chlamydia or gonorrhoea between regimens using Poisson regression. The study period was from 3 August 2015 until 24 September 2018.Results and discussionWe included 571 MSM, of whom 148 (25.9%) chose edPrEP at baseline. 31.7% of participants switched regimen at least once. After 28 months, 23.5% used edPrEP. Older participants (adjusted odds ratio (aOR) = 1.38 per 10 years, 95% confidence interval (CI) = 1.15 to 1.64) and those unemployed (aOR = 1.68, 95% CI = 1.03 to 1.75) were more likely to initially choose edPrEP. IR of HCV and syphilis did not differ between regimens, but the IR of chlamydia/gonorrhoea was higher among daily users (adjusted incidence rate ratio = 1.61, 95% CI = 1.35 to 1.94).ConclusionsA quarter of participants chose edPrEP at baseline and at 28 months this proportion was similar. Although the IR of HCV and syphilis were similar in the two regimens, the lower incidence of chlamydia and gonorrhoea among edPrEP users may suggest that less frequent STI testing of this group could be considered. 相似文献
123.
GM Repetto ML Guzmán A Puga JF Calderón CP Astete M Aracena M Arriaza T Aravena P Sanz 《Clinical genetics》2009,76(5):465-470
Patients with chromosome 22q11 deletion syndrome exhibit significant phenotypic variability. Epidemiologic data suggest a higher incidence in Hispanics, but limited clinical information is available from Latin-American patients. We describe the clinical features of Chilean patients with 22q11 deletion syndrome and compare their findings with those reported in large European, Japanese and US series. Data were obtained from 208 patients from five medical centers. Mean age at diagnosis was 5.2 years, with a median of 2.3 years. Congenital heart defects were present in 59.6%, lower than other large series that averaged 75.8%. Palate abnormalities were present in 79%, higher than previous reports averaging 56%. Patients with congenital heart disease were diagnosed earlier (median 0.3 years of age) than those without heart defects (median 5.6 years) and had greater mortality attributable to the syndrome (9.8% vs 2.4%, respectively). The differences in frequencies of major anomalies may be due to growing awareness of more subtle manifestations of the syndrome, differences in clinical ascertainment or the presence of modifier factors. These observations provide additional data useful for patient counseling and for the proposal of health care guidelines. 相似文献
124.
125.
126.
127.
D Gómez-Garre P Mu?oz-Pacheco ML González-Rubio P Aragoncillo R Granados A Fernández-Cruz 《British journal of pharmacology》2009,156(8):1218-1227
Background and purpose:
Ezetimibe, a selective inhibitor of intestinal cholesterol absorption, might also suppress inflammatory components of atherogenesis. We have studied the effects of ezetimibe on two characteristics of atherosclerotic plaques (infiltrate and fibrosis) and on expression of inflammatory genes in a rabbit model of accelerated atherosclerosis.Experimental approach:
Femoral atherosclerosis was induced by a combination of endothelial desiccation and atherogenic diet. Animals were randomized to ezetimibe (0.6 mg·kg−1·day−1), simvastatin (5 mg·kg−1·day−1), ezetimibe plus simvastatin or no treatment, still on atherogenic diet. A control group of rabbits received normolipidemic diet.Key results:
Rabbits fed the normolipidemic diet showed normal plasma lipid levels. Either the normolipidemic diet or drug treatment reduced the intima/media ratio (normolipidemic diet: 22%, ezetimibe: 13%, simvastatin: 27%, ezetimibe + simvastatin: 28%), compared with rabbits with atherosclerosis. Ezetimibe also decreased macrophage content and monocyte chemoattractant protein-1 expression in atherosclerotic lesions. Furthermore, ezetimibe reduced the increased activity of nuclear factor κB in peripheral blood leucocytes and plasma C-reactive protein levels in rabbits with atherosclerosis. In THP-1 cells, ezetimibe decreased monocyte chemoattractant protein-1-induced monocyte migration. Importantly, the combination of ezetimibe with simvastatin was associated with a more significant reduction in plaque monocyte/macrophage content and some proinflammatory markers than observed with each drug alone.Conclusions and implications:
Ezetimibe had beneficial effects both on atherosclerosis progression and plaque stabilization and showed additional anti-atherogenic benefits when combined with simvastatin. Its effect on monocyte migration provides a potentially beneficial action, in addition to its effects on lipids. 相似文献128.
Yip Ronald ML Cheung Tommy T So Ho Chan Julia PS Ho Carmen TK Tsang Helen HL Yu Carrel KL Wong Priscilla CH 《Clinical rheumatology》2023,42(8):2013-2027
Clinical Rheumatology - Gout is one of the most common noncommunicable diseases in Hong Kong. Although effective treatment options are readily available, the management of gout in Hong Kong remains... 相似文献
129.
Schwarz M Spath L Lux CA Paprotka K Torzewski M Dersch K Koch-Brandt C Husmann M Bhakdi S 《Thrombosis and haemostasis》2008,100(1):110-118
Following entrapment in the arterial intima, low-density lipoprotein (LDL) can be modified by hydrolytic enzymes to yield a lipoprotein derivative that binds C-reactive protein, activates complement, and is rapidly taken up by monocytes/macrophages. Free fatty acids contained in enzymatically modified LDL (E-LDL) render the lipoprotein cytotoxic due to their capacity to trigger programmed cell death. Apoprotein J (ApoJ) alias clusterin is a multifunctional glycoprotein with cytoprotective and anti-inflammatory properties. It interacts with diverse substrates, is present in the intima and the media of arteries with atherosclerotic lesions and is also synthesized by smooth muscle cells during development of atherosclerosis. We report that ApoJ binds to E-LDL but not to native LDL. Binding resulted in marked reduction of cytotoxicity of E-LDL on smooth muscle cells, as revealed by determination of caspase activity, annexin binding, and cellular ATP. ApoJ was detected immunohistochemically in early atherosclerotic lesions, where it was found to co-localize with E-LDL. In atherosclerotic lesions, ApoJ may thus subserve protective functions through its capacity to inactivate C5b-9 complement complexes and by reducing the cytotoxic effects of modified LDL on cells that gain contact with the lipoprotein. 相似文献
130.